Medtronic to Acquire Contego Medical

The deal targets the recently FDA-approved Neuroguard IEP Direct System.

Medtronic corporate headquarters building with modern glass and concrete facade on green lawn
JHVEPhoto/iStock

Medtronic said it plans to acquire Contego Medical, a privately held medical device company focused on solutions for carotid artery disease and peripheral thrombectomy.

The deal is valued at $380 million. The companies expect to close later this year.

The acquisition will build on the company's exclusive U.S. distribution agreement with Contego, first announced in January 2025, and advances the Medtronic strategy of pursuing targeted investments that strengthen the company's core franchises. The deal expands the Medtronic portfolio of carotid technologies, broadening patient access to innovative therapies for carotid artery and peripheral vascular disease.

"With this acquisition, Medtronic is taking another important step to strengthen our leadership in the treatment of carotid artery disease," said David Moeller, senior vice president and president of Medtronic Peripheral Vascular Health, which is part of the company's Cardiovascular portfolio. "By pairing Medtronic's deep clinical expertise in peripheral and neurovascular technologies with Contego's next-generation treatments backed by strong and consistent clinical data, we intend to become an undisputed leader in carotid revascularization."

The planned acquisition includes Contego's recently FDA-approved Neuroguard IEP Direct System, one of the first transcarotid artery revascularization systems with integrated embolic protection (TCAR-IEP) in addition to flow reversal.

"Stroke-related disability underscores the need for more innovative treatment options — and the opportunity to make a meaningful difference for patients," said Linnea Burman, senior vice president and president of Medtronic Neurovascular.  "We are committed to delivering technologies designed to reduce stroke risk and advance patient care. Our planned acquisition of Contego builds on that commitment, helping physicians bring meaningful innovation to more patients with carotid artery disease."

Beyond carotid revascularization, the acquisition includes Contego's Excipio thrombectomy devices, which complement Medtronic's Liberant thrombectomy system in the treatment of peripheral vascular disease.

More in Devices